Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts.

Rimawi MF, Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, Gutierrez C, Hilsenbeck SG, Arpino G, Massarweh S, Ward R, Soliz R, Osborne CK, Schiff R.

Clin Cancer Res. 2011 Mar 15;17(6):1351-61. doi: 10.1158/1078-0432.CCR-10-1905. Epub 2010 Dec 7.

PMID:
21138857
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.

Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne CK, Schiff R.

J Natl Cancer Inst. 2007 May 2;99(9):694-705.

PMID:
17470737
[PubMed - indexed for MEDLINE]
Free Article
3.

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.

Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R.

Breast Cancer Res. 2011;13(6):R121. doi: 10.1186/bcr3067. Epub 2011 Nov 28.

PMID:
22123186
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, Di Cosimo S, Matias-Guiu X, Ramon y Cajal S, Arribas J, Baselga J.

J Natl Cancer Inst. 2007 Apr 18;99(8):628-38.

PMID:
17440164
[PubMed - indexed for MEDLINE]
Free Article
5.

Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.

Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL.

Clin Cancer Res. 2013 Feb 1;19(3):610-9. doi: 10.1158/1078-0432.CCR-12-2024. Epub 2012 Dec 5.

PMID:
23224399
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.

Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R.

Breast Cancer Res. 2011 Aug 31;13(4):R84. doi: 10.1186/bcr2936.

PMID:
21884573
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.

Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ, Finn RS.

Clin Cancer Res. 2010 Mar 1;16(5):1509-19. doi: 10.1158/1078-0432.CCR-09-1112. Epub 2010 Feb 23.

PMID:
20179222
[PubMed - indexed for MEDLINE]
Free Article
8.

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL.

Cancer Res. 2001 Dec 15;61(24):8887-95.

PMID:
11751413
[PubMed - indexed for MEDLINE]
Free Article
9.
10.

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.

Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramon y Cajal S, Arribas J, Baselga J.

Oncogene. 2009 Feb 12;28(6):803-14. doi: 10.1038/onc.2008.432. Epub 2008 Dec 8.

PMID:
19060928
[PubMed - indexed for MEDLINE]
11.

Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.

Seoane S, Montero JC, Ocaña A, Pandiella A.

J Natl Cancer Inst. 2010 Sep 22;102(18):1432-46. doi: 10.1093/jnci/djq315. Epub 2010 Sep 1.

PMID:
20811002
[PubMed - indexed for MEDLINE]
Free Article
12.

Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.

Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, Liewehr DJ, Steinberg SM, Merino MJ, Rubin SD, Steeg PS.

J Natl Cancer Inst. 2008 Aug 6;100(15):1092-103. doi: 10.1093/jnci/djn216. Epub 2008 Jul 29.

PMID:
18664652
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ.

Cancer Res. 2006 Feb 1;66(3):1630-9.

PMID:
16452222
[PubMed - indexed for MEDLINE]
Free Article
15.

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.

Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC.

J Clin Oncol. 2011 Jan 10;29(2):166-73. doi: 10.1200/JCO.2009.27.7814. Epub 2010 Dec 6.

PMID:
21135276
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.

Larbouret C, Gaborit N, Chardès T, Coelho M, Campigna E, Bascoul-Mollevi C, Mach JP, Azria D, Robert B, Pèlegrin A.

Neoplasia. 2012 Feb;14(2):121-30.

PMID:
22431920
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.

Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Menendez JA.

J Cell Physiol. 2011 Jan;226(1):52-7. doi: 10.1002/jcp.22333.

PMID:
20658522
[PubMed - indexed for MEDLINE]
18.

Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.

Diermeier-Daucher S, Breindl S, Buchholz S, Ortmann O, Brockhoff G.

Cytometry A. 2011 Sep;79(9):684-93. doi: 10.1002/cyto.a.21107. Epub 2011 Jul 22.

PMID:
21786419
[PubMed - indexed for MEDLINE]
Free Article
19.

Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.

O'Donovan N, Byrne AT, O'Connor AE, McGee S, Gallagher WM, Crown J.

Invest New Drugs. 2011 Oct;29(5):752-9. doi: 10.1007/s10637-010-9415-5. Epub 2010 Mar 16.

PMID:
20229355
[PubMed - indexed for MEDLINE]
20.

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.

Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F.

Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9.

PMID:
21153051
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk